N. Moosmann

发表

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial

M. Stauch, V. Heinemann, H. Hass, 2011, British Journal of Cancer.

Cetuximab in the treatment of metastatic colorectal cancer

V. Heinemann, N. Moosmann, 2007, Expert opinion on biological therapy.

Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

M. Stauch, V. Heinemann, T. Decker, 2020, Clinical Cancer Research.

Impact of exact segment by segment primary tumor location status on anti-EGFR antibody first-line treatment efficacy in RAS/BRAF wild-type and BRAF mutant metastatic colorectal cancer. A pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.

V. Heinemann, T. Decker, A. Tannapfel, 2021 .

V. Heinemann, A. Wollenberg, J. Neumann, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy

V. Heinemann, T. Decker, A. Tannapfel, 2022, Cancers.

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases: The PARLIM trial (AIO KRK 0314).

V. Heinemann, S. Kasper, C. Junghanss, 2021, Journal of Clinical Oncology.

Hepatic artery infusion of 5-fluorouracil, folinic acid plus oxaliplatin for liver metastasis from colorectal cancer. Final analysis of a phase I/II studay

W. Hiddemann, V. Heinemann, W. Kern, 2005 .

A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition

A. Wollenberg, K. Katzer, N. Moosmann, 2008, Experimental dermatology.

Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC).

M. Stauch, V. Heinemann, D. Oruzio, 2010 .

Cetuximab + capecitabine + irinotecan (CCI) versus cetuximab + capecitabine + oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): Preliminary results of a randomized phase II trial of the AIO CRC Study Group.

M. Stauch, V. Heinemann, D. Oruzio, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.

M. Stauch, V. Heinemann, H. Hass, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform exanthema caused by the EGFR-inhibitor cetuximab

V. Heinemann, A. Wollenberg, T. Ruzicka, 2008 .

[Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid].

V. Heinemann, A. Wollenberg, J. Kroth, 2007, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group

V. Heinemann, A. Wollenberg, J. Neumann, 2013, International journal of cancer.

The Treatment of Colorectal Carcinoma With Monoclonal Antibodies

W. Hiddemann, V. Heinemann, T. Kirchner, 2009 .

The influence of KRAS and BRAF mutations on the efficacy of cetuximab‐based first‐line therapy of metastatic colorectal cancer: An analysis of the AIO KRK‐0104‐trial

V. Heinemann, J. Neumann, T. Kirchner, 2012, International journal of cancer.

Effective Second-Line Treatment with Cetuximab and Bevacizumab in a Patient with Hepatic Metastases of Colorectal Cancer and Hyperbilirubinemia

V. Heinemann, H. Michaely, C. Schulz, 2007, Oncology Research and Treatment.

Waterfall plot analysis of XELOX or XELIRI with cetuximab or bevacizumab in patients with advanced colorectal cancer (ACRC): Combined analysis of two randomized first-line phase II trials of the AIO CRC study group

S. Kubicka, A. Hinke, V. Heinemann, 2008 .

Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer

V. Heinemann, N. Moosmann, 2008, Expert review of anticancer therapy.

Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.

V. Heinemann, N. Moosmann, 2008, Clinical colorectal cancer.

Differential role of extra- and intracellular superoxide anions for nitric oxide-mediated apoptosis induction.

G. Bauer, N. Moosmann, M. Schimmel, 2004, In vivo.

Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer

V. Heinemann, R. Issels, S. Boeck, 2008, Oncology.

Erythroblastic synartesis in a patient initially diagnosed with myelodysplastic syndrome

W. Hiddemann, T. Haferlach, H. Ostermann, 2005, Annals of Hematology.

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial

M. Bangerter, A. Hinke, V. Heinemann, 2011, BMC Cancer.

Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.

D. Ankerst, V. Heinemann, R. Laubender, 2011, Clinical colorectal cancer.

The influence of KRAS and BRAF mutations on the efficacy of cetuximab‐based first‐line therapy of metastatic colorectal cancer: An analysis of the AIO KRK‐0104‐trial

C. Giessen, C. Schulz, M. Haas, 2012, International journal of cancer.

Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group

M. Stauch, V. Heinemann, H. Hass, 2008 .

“En bloc” caudate lobe and inferior vena cava resection following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal and liver metastasis of colorectal cancer

P. Piso, P. Sánchez-Velázquez, I. Töpel, 2016, World journal of gastroenterology.

Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial

J. Gaedcke, Peter Jo, N. Moosmann, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)

T. Ettrich, G. Siegler, N. Homann, 2023, Frontiers in oncology.

The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.

W. Hiddemann, V. Heinemann, T. Kirchner, 2009, Deutsches Arzteblatt international.

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314).

K. Kaczirek, A. Kiani, M. Karthaus, 2022, European journal of cancer.